Joanna Drowos, D.O., M.P.H., M.B.A., FAU Schmidt College of Medicine, provides answers to some of the most frequently asked questions regarding the COVID-19 boosters and vaccines for children ages 5 to 11.
Simon Li, a principal investigator in the Rutgers pediatric clinical trial for the Pfizer-BioNTech COVID-19 vaccine, addresses parents’ questions
With two viruses threatening to make older adults sick this winter, a new poll shows most people over 50 have gotten protected by vaccines against both influenza and coronavirus, or plan to. And a majority of those who have gotten the COVID-19 vaccine plan to get an additional dose. But the poll also reveals major differences in vaccine attitudes between older adults, including those of different political leanings.
SEATTLE — Nov. 2, 2021 — Below are summaries of recent Fred Hutch research findings and other news.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that people with chronic inflammatory diseases, such as rheumatoid arthritis (RA), who take immunosuppressive therapy appear to have an impaired immunity response to SARS-CoV-2, the coronavirus that causes COVID-19, vaccines. Patients currently on glucocorticoids or B-cell depleting therapy appear to have an even more severely impeded vaccine response.
In a newly published study, researchers at the University of Maryland School of Medicine have detected antibodies primarily made in response to infections in the mucous membranes — in such areas as the lungs, intestines, or vagina — in study participants with malaria.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that in Alabama, one in 10 racial or ethnic minority patients with a rheumatic disease in a large rheumatology clinic said they were unlikely to get vaccinated against COVID-19.
The Morgridge Institute for Research will broadcast a free webinar on November 9, featuring a conversation with experts on the front lines of pediatric vaccine development and public health.
The University of Delaware's Aditya Kunjapur has been awarded the 2021 American Institute of Chemical Engineers (AIChE) Langer Prize for Innovation and Entrepreneurial Excellence, a highly competitive award that comes with a stipend to pursue “blue sky” ideas.
Researchers at Cedars-Sinai found that patients with inflammatory bowel disease (IBD)─whose treatment can weaken the immune system─produced a strong antibody response to COVID-19 vaccination. The study findings have been published in the Annals of Internal Medicine.
Following FDA authorization of the COVID-19 vaccine for 5- to 11-year-olds, Together by St. Jude releases a free coloring book that educates children on COVID-19 vaccines.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows patients using rituximab were able to produce antibodies against COVID-19 after receiving a third vaccine dose, even if there was no development of the antibody after the first two.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that nearly 30% of patients with lupus in a multi-ethnic and multi-racial study had a low response to the new COVID-19 vaccines.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that the COVID-19 vaccine was not associated with severe disease flares in patients with rheumatic diseases.
In what is believed to be one of the largest studies of its kind, Johns Hopkins Medicine researchers have shown that antibody levels against SARS-CoV-2 (the COVID-19 virus) stay more durable — that is, remain higher over an extended period of time — in people who were infected by the virus and then received protection from two doses of messenger RNA (mRNA) vaccine compared with those who only got immunized.
NYU Langone rheumatologists are presenting their discoveries at the annual American College of Rheumatology conference, November 1 to November 9. The conference will be held virtually.
What if a few minutes of interaction with a chatbot could effectively address vaccine concerns?
As the Food and Drug Administration edges closer to emergency use approval of the Pfizer COVID-19 vaccine for children ages 5-11 – which could become available as soon as early November – Rutgers faculty and staff share reasons for why they'll vaccinate their children.
New UCLA research finds that misinformation and politicization, awareness of past injustices involving medical research, and fears about the inequitable distribution of vaccines all contributed to hesitancy to be vaccinated among Los Angeles' People of Color.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
